New study hopes to outsmart pancreatic cancer by gathering clues

NCT ID NCT05692596

Knowledge-focused Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No new treatments are being tested; instead, the focus is on learning from existing patient data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this could lead to better ways to detect pancreatic cancer early or prevent it, potentially saving lives.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly benefit participants. Results may take years and might not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 317 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting at the Moffitt GI clinic

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC) * Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC. * Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ataxia-telangiectasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ataxia telangiectasia chronic pancreatitis classic familial adenomatous polyposis Colorectal Neoplasms, Hereditary Nonpolyposis familial atypical multiple mole melanoma syndrome hereditary chronic pancreatitis Lynch syndrome melanoma, cutaneous malignant, susceptibility to, 2 PALB2-related cancer predisposition Pancreatic Cyst pancreatic ductal adenocarcinoma Peutz-Jeghers syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ataxia-telangiectasia BRCA mutation Chronic pancreatitis Familial atypical multiple mole-melanoma FAP Fatty pancreas Genetic pancreatic cancer Genetic pancreatitis Lynch syndrome PALB2 gene mutation Pancreatic cyst Pancreatic ductal adenocarcinoma Peutz-Jeghers syndrome

New study hopes to outsmart pancreatic cancer by gathering clues

What the study statuses mean